Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carol Banyas

Psychosomatic Medicine Danville, CA Medical Doctor

NPI 1881806313 CMS profile 673461

203 Sycamore Valley Rd W, Danville, CA 94526

Open in the dashboard

General payments

$1,814

36 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carol Banyas of Danville, CA is reported in the CMS Open Payments database as having received $1,814 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychosomatic Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $831 16
2024 General $251 7
2023 General $361 7
2022 General $34 1
2021 General $337 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Banyas
  • Psychosomatic Medicine median
  • Middle half of Psychosomatic Medicine
  • National median

In program year 2025, general payments to Carol Banyas were reported at $831. Among 72 Psychosomatic Medicine profiles paid that year, the median was $152 and the middle half received between $47 and $428.

Show as a table
Year Carol Banyas Psychosomatic Medicine median Middle half National median
2019 $0 $125 $51–$524 $163
2020 $0 $117 $29–$251 $114
2021 $337 $123 $33–$366 $132
2022 $34 $107 $37–$450 $149
2023 $361 $131 $57–$397 $160
2024 $251 $122 $27–$293 $164
2025 $831 $152 $47–$428 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Vanda Pharmaceuticals Inc. $573 10 payments
  2. Otsuka America Pharmaceutical, Inc. $405 9 payments
  3. Neuronetics, Inc. $274 2 payments
  4. Alkermes, Inc. $220 5 payments
  5. Janssen Pharmaceuticals, Inc $143 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $97 4 payments
  7. Bausch Health US, LLC $31 1 payment
  8. Lundbeck LLC $30 1 payment
  9. E.R. Squibb & Sons, L.L.C. $21 1 payment
  10. Acella Pharmaceuticals, LLC $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,814 36 payments
Products named General payments · program years 2021–2025
  1. FANAPT $573 10 payments
  2. NEUROSTAR TMS THERAPY $274 2 payments
  3. REXULTI $263 7 payments
  4. LYBALVI Cns $220 5 payments
  5. ABILIFY MAINTENA $195 4 payments
  6. SPRAVATO $143 2 payments
  7. LYBALVI Cns $122 1 payment
  8. LYBALVI Cns $122 1 payment
  9. LYBALVI Cns $122 1 payment
  10. ARISTADA $98 4 payments
  11. Other $489 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

246

Median for Neuropsychiatry: 88

Drug cost

$3,393

Median for Neuropsychiatry: $2,689

Branded share of claims

16.7%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 31 $960
Quetiapine Fumarate Generic 42 $836
Liothyronine Sodium Generic 24 $525
Bupropion Xl Bupropion Hcl Brand 41 $353
Mirtazapine Generic 29 $195
Buspirone Hcl Generic 17 $180
Hydroxyzine Pamoate Generic 12 $141
Escitalopram Oxalate Generic 20 $140
Trazodone Hcl Generic 16 $44
Alprazolam Generic 14 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $167
$167 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $43
$43 — —
NP Thyroid 60
  • Acella Pharmaceuticals, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychosomatic Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record